The Haveras are teaming up to raise money for the Leukemia and Lymphoma Society's annual Light the Night walk. The Haveras are teaming up to raise money for the Leukemia and Lymphoma Society's annual ...

BUFFALO, N.Y. — A 6-year-old who was diagnosed with a rare form of leukemia is in remission and ready for first grade after receiving an innovative cancer treatment at Roswell Park Comprehensive Care ...

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...

Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated. The tool, called MARLIN (Methylation- ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and ...

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve ...